Published Paper Details:

ABSTRACT Background: A disorder known as gastro-esophageal reflux disease develops when stomach acid reflux causes unpleasant symptoms and/or consequences. Proton pump inhibitors (PPIs) are used in gastric acid suppression therapy to treat GERD. Here, Rabeprazole used since it provides better efficacy than other PPIs and Itopride a novel gastro prokinetic agent stimulate the movement of the gastrointestinal tract, which speeds up the emptying of the stomach and modifies the sensorimotor function of the stomach. When prokinetic drugs like itopride and proton pump inhibitors are used together to treat gastro-esophageal reflux disease, they work in combination to reduce acid production and improve therapeutic response. Aim: To compare the quality of life and medication adherence in patients taking Rabeprazole monotherapy versus Rabeprazole and Itopride combination therapy in gastro-esophageal reflux disease. Objective: The objectives of the study include o To assess the quality of life. o To assess the medication adherence. Materials and Methods: The prospective observational comparative study was carried out in 30 patients with GERD. Patients were assigned into two groups, Group A and Group B. Group A received Rabeprazole 20mg twice daily as monotherapy and group B received Rabeprazole and Itopride 20/150mg once daily as combination therapy; 30 minutes before food respectively for 0, 4 and 8 weeks. Patient's Quality of Life will be measured at the beginning of the therapy and patient counselling will be done using Patient Information Leaflet (PIL), then follow-up was taken after 4th and 8th weeks of treatment using Gastroesophageal Reflux Disease-Health Related Quality of Life questionnaire (GERD-HRQL). Patient's medication adherence will be assessed by using Adherence to Refill and Medication Scale (ARMS).